Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022. Patrik Jonsson, senior vice president and president of Lilly Immunology, will engage in a fireside chat at 10:15 a.m. ET. Investors and the public can access a live audio webcast through Lilly's Investor website. A replay will be available for approximately 90 days. Lilly continues its commitment as a global healthcare leader, dedicated to discovering life-changing medicines.

Eli Lilly and Boehringer Ingelheim announced that Jardiance (empagliflozin) demonstrated a 36% higher clinical benefit in adults hospitalized for acute heart failure in the EMPULSE phase III trial, compared to placebo. The study, comprising 530 patients, evaluated composite endpoints including mortality and frequency of heart failure events. Jardiance also improved quality of life as measured by the Kansas City Cardiomyopathy Questionnaire. The FDA has previously approved Jardiance for reducing cardiovascular death risk in heart failure patients, contributing to its third approval related to the EMPOWER program.

Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on March 8, 2022. Anat Ashkenazi, Lilly's CFO, will engage in a virtual fireside chat at 10:30 a.m. Eastern Time. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly is dedicated to creating high-quality medicines and enhancing community well-being through philanthropy. For more details, visit www.lilly.com.

The FDA has approved Jardiance (empagliflozin) 10 mg for reducing the risk of cardiovascular death and hospitalization for heart failure in adults. This marks a significant advancement for nearly 3 million U.S. adults with heart failure with preserved ejection fraction, expanding treatment options in a sector with limited alternatives. Jardiance previously received approval for heart failure with reduced left ventricular ejection fraction. The approval is based on the EMPEROR-Preserved phase III trial, which showed a 21% risk reduction in cardiovascular events.

Eli Lilly and Company (NYSE: LLY) has launched the Lilly Institute for Genetic Medicine with a $700 million investment to establish a new facility in Boston Seaport. This initiative aims to advance RNA-based therapeutics, leveraging existing expertise from its 2020 acquisition of Prevail Therapeutics. The Boston site plans to grow its team from 120 to over 250 specialists over the next five years. Additionally, the facility will support biotech start-ups, potentially creating 150 new jobs. The Institute is expected to enhance research in neurodegenerative diseases.

In the pivotal LUCENT-1 Phase 3 study, Eli Lilly's mirikizumab demonstrated statistically superior clinical remission rates at 12 weeks in patients with moderately-to-severely active ulcerative colitis, achieving 24.2% versus 13.3% for placebo (p=0.00006). Key secondary endpoints also showed significant improvements, with 63.5% of patients responding to treatment. Mirikizumab's safety profile was consistent with previous studies, reporting lower serious adverse events (2.8% vs. 5.3% for placebo). Lilly plans to submit a Biologics License Application to the FDA in early 2022.

Eli Lilly and Company (NYSE: LLY) has launched a new education campaign aimed at raising awareness of breast cancer recurrence risks. Collaborating with organizations like Breastcancer.org and Living Beyond Breast Cancer, the initiative focuses on individuals diagnosed with hormone receptor-positive, HER2-negative early breast cancer. With over 290,000 expected diagnoses in the U.S. in 2022, the campaign provides resources to help patients understand individual risk factors for recurrence. Educational materials include a digital fact sheet and patient conversation guide.

Eli Lilly (NYSE: LLY) announced that the FDA has granted Emergency Use Authorization (EUA) for its monoclonal antibody, bebtelovimab, to treat mild-to-moderate COVID-19 in high-risk adults and pediatric patients. The treatment is authorized for patients with positive SARS-CoV-2 tests who lack suitable alternatives. The recommended dose is 175 mg via intravenous injection. Eli Lilly has secured a supply agreement with the U.S. government for 600,000 doses, valued at approximately $720 million. Bebtelovimab retains efficacy against Omicron and other variants of concern.

Eli Lilly and Company (NYSE: LLY) announced a contract with the U.S. government to supply up to 600,000 doses of the investigational COVID-19 treatment, bebtelovimab, for at least $720 million. The agreement is contingent on the drug receiving Emergency Use Authorization (EUA) from the FDA, a request that has been submitted. The projected revenue impact for 2022 is at least $720 million, with an estimated $0.20 in earnings per share (EPS). Bebtelovimab demonstrates strong efficacy against COVID-19 variants, maintaining full neutralizing activity against Omicron and other variants of concern.